OCS · Company research
Oculis Holding AG Ordinary shares (OCS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting | Oculis announced it will present new biomarker data from its Phase 2 ACUITY trial of Privosegtor at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto on October 21-23, 2026. The presentation will highlight plasma NfL and GFAP biomarker analyses demonstrating neuroprotective potential in acute optic neuritis patients. Privosegtor has received FDA Breakthrough Therapy and EMA PRIME designations, with the company planning registrational trials through its PIONEER program. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki | Oculis announced completion of randomization in the PREDICT-1 registrational trial for Licaminlimab, a precision medicine treatment for TNFR1-mediated dry eye disease. The trial enrolled 176 patients, with two-thirds carrying the specific TNFR1 genetic variant associated with improved clinical response. Topline results are expected around year-end 2026. If approved, Licaminlimab could become the first precision medicine treatment for an estimated 1.5 million Americans with moderate to severe TNFR1-mediated dry eye disease. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| OCS Oct 2026 5.000 put (OCS261016P00005000) Stock Price, News, Quote & History - Yahoo! Finance Canada | OCS Oct 2026 5.000 put (OCS261016P00005000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| (OCS) Risk Channels and Responsive Allocation - Stock Traders Daily | (OCS) Risk Channels and Responsive Allocation Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 15, 2026 | neutral | 0 | 0.6 |
| OCS Nov 2026 12.500 put (OCS261120P00012500) Interactive Stock Chart - Yahoo! Finance Canada | OCS Nov 2026 12.500 put (OCS261120P00012500) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| OCS Nov 2026 12.500 put (OCS261120P00012500) Stock Price, News, Quote & History - Yahoo! Finance Canada | OCS Nov 2026 12.500 put (OCS261120P00012500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Oculis Holding AG (OCS) Edges 0.69% Lower to $8.60, Holding the Middle of Its Recent Range - Put Support - siam.in | Oculis Holding AG (OCS) Edges 0.69% Lower to $8.60, Holding the Middle of Its Recent Range - Put Support siam.in | View source ↗ | siam.in | Oct 9, 2026 | neutral | 0 | 0.6 |
| Oculis Holding (NasdaqGM:OCS) Stock Forecast & Analyst Predictions - Simply Wall Street | Oculis Holding (NasdaqGM:OCS) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance Singapore | Oculis Holding AG (OCS) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 8, 2026 | neutral | 0 | 0.6 |
| Trial results for a potential dry eye drug are on track for around year-end, Oculis says. - Stock Titan | Trial results for a potential dry eye drug are on track for around year-end, Oculis says. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day | Oculis announced that CEO Riad Sherif will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at Eyecelerator @ AAO 2026 on October 8. The company's PREDICT-1 registrational trial is on track for topline readout around year-end. Oculis will also sponsor the Neuro-Ophthalmology Subspecialty Day, highlighting its commitment to advancing neuro-ophthalmology research and innovation. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day | Oculis announced that CEO Riad Sherif will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at Eyecelerator @ AAO 2026 on October 8. The company's PREDICT-1 registrational trial is on track for topline readout around year-end. Oculis will also sponsor the Neuro-Ophthalmology Subspecialty Day, highlighting its commitment to advancing neuro-ophthalmology research and innovation. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| (OCS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily | (OCS) Price Dynamics and Execution-Aware Positioning Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 5, 2026 | neutral | 0 | 0.6 |
| (OCS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily | (OCS) Price Dynamics and Execution-Aware Positioning Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 5, 2026 | neutral | 0 | 0.6 |
| Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot - The Globe and Mail | Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| Eight directors remain at Oculis (OCS) after a board member serving since 2017 resigns. - Stock Titan | Eight directors remain at Oculis (OCS) after a board member serving since 2017 resigns. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Citi Sees $11 Billion Optical Networking Boom Driven By Google, Nvidia - Investor's Business Daily | Citi Sees $11 Billion Optical Networking Boom Driven By Google, Nvidia Investor's Business Daily | View source ↗ | Investor's Business Daily | Sep 28, 2026 | neutral | 0 | 0.6 |
| Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS) - Seeking Alpha | Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 17, 2026 | neutral | 0 | 0.6 |
| Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Yahoo Finance | Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| OCS Stock Price and Chart — NASDAQ:OCS - TradingView | OCS Stock Price and Chart — NASDAQ:OCS TradingView | View source ↗ | TradingView | Jun 4, 2026 | neutral | 0 | 0.6 |
| OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud - Business Wire | OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud Business Wire | View source ↗ | Business Wire | Jun 3, 2026 | neutral | 0 | 0.6 |
| Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) - PR Newswire | Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) PR Newswire | View source ↗ | PR Newswire | Jun 1, 2026 | neutral | 0 | 0.6 |
| Oculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development Programs | OCS Stock News - Quiver Quantitative | Oculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development Programs | OCS Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | May 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.